Sona Nanotech Inc.

Sona Nanotech Inc. is a nanotechnology life sciences company based in Halifax, Nova Scotia, Canada, with its corporate office at Purdy's Wharf Tower II and an R&D office in Dartmouth. Founded in 2013, the company's core business revolves around the development of next-generation diagnostic products and medical applications, with a mission to transform cancer treatment through its patented, uniquely biocompatible gold nanorod technology.

Sona Nanotech specializes in the production of CTAB-free gold nanoparticles, including Gold Nanorods (GNRs) and Gold Nanospheres, which are crucial for its therapeutic and diagnostic applications. The company's primary focus in therapeutics is its Targeted Hyperthermia Therapy (THT) for solid cancer tumors, which uses infrared light absorbed by its gold nanorods to generate therapeutic heat. Beyond cancer therapy, Sona's gold nanoparticles are also utilized in diagnostic testing, such as ELISA and lateral flow assays, and for drug delivery.

Recent notable developments for Sona Nanotech include the appointment of Michael A. Fleming to its Board of Directors in June 2026 and the announcement of a clinical strategy for two THT combination therapy studies in melanoma in May 2026. In 2025, the company reported compelling early human efficacy from a study where the first patient was dosed with its gold nanorod technology for immunotherapy-resistant melanoma, showing an 80% overall response rate. Sona Nanotech also successfully completed bacterial endotoxin testing on its gold nanorods in May 2025, a critical step for its first-in-human clinical studies. The company's leadership includes CEO David Regan, CMO Dr. Carman Giacomantonio, and CSO Dr. Len Pagliaro, with Mark Lievonen serving as the Chair of the Board.